Marshall Wace LLP Has $412,000 Stock Holdings in Sensus Healthcare, Inc. (NASDAQ:SRTS)

Marshall Wace LLP boosted its position in shares of Sensus Healthcare, Inc. (NASDAQ:SRTS) by 152.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 77,387 shares of the company’s stock after purchasing an additional 46,732 shares during the period. Marshall Wace LLP owned about 0.47% of Sensus Healthcare worth $412,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in SRTS. Chapin Davis Inc. bought a new position in shares of Sensus Healthcare in the second quarter valued at approximately $53,000. Creekmur Asset Management LLC acquired a new position in Sensus Healthcare in the fourth quarter worth $83,000. XTX Topco Ltd acquired a new position in Sensus Healthcare in the second quarter worth $95,000. Hillsdale Investment Management Inc. bought a new stake in shares of Sensus Healthcare during the first quarter worth $155,000. Finally, Acadian Asset Management LLC raised its holdings in shares of Sensus Healthcare by 578.6% in the second quarter. Acadian Asset Management LLC now owns 45,124 shares of the company’s stock valued at $239,000 after buying an additional 38,474 shares during the last quarter. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Price Performance

NASDAQ:SRTS opened at $6.32 on Friday. The company has a market cap of $103.60 million, a P/E ratio of 21.41 and a beta of 1.05. Sensus Healthcare, Inc. has a twelve month low of $1.79 and a twelve month high of $7.18. The business has a 50 day moving average price of $6.19 and a two-hundred day moving average price of $5.34.

Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 8th. The company reported $0.10 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.07. Sensus Healthcare had a return on equity of 13.46% and a net margin of 18.27%. The business had revenue of $9.24 million for the quarter, compared to analyst estimates of $7.00 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. As a group, analysts anticipate that Sensus Healthcare, Inc. will post 0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the company. Roth Capital raised Sensus Healthcare to a “strong-buy” rating in a report on Friday, July 12th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Sensus Healthcare in a research note on Monday, August 12th.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.